Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors Y. Shi, X. Hu, S. Zhang, N. Yang, Y. Zhang, W. Li, X. Han, H. Mo, Y. Sun
Title P2.03-028 Third Generation EGFR Inhibitor AST2818 (Alflutinib) in NSCLC Patients with EGFR T790M Mutation: A phase1/2 Multi-Center Clinical Trial
URL https://www.jto.org/article/S1556-0864(17)32014-2/abstract
Abstract Text J Thorac Oncol. Nov 2017, Vol 12, Issue 11, Suppl. 2, pS2138

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Furmonertinib Furmonertinib 0 2
Drug Name Trade Name Synonyms Drug Classes Drug Description
Furmonertinib AST2818|AST2818|Alflutinib EGFR Inhibitor 3rd gen 26 Furmonertinib (alflutinib) is a third-generation EGFR inhibitor that targets both EGFR activating mutations and T790M, potentially leading to tumor growth inhibition (PMID: 33780662, PMID: 35662408).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References